Peculiarities of dabigatran pharmacogenetics: literature review

Abstract

Dabigatran is highly effective oral anticoagulant used in patients with atrial fibrillation, venous thrombosis, pulmonary embolism, orthopedic surgery. The most important role in activation and transport of dabigatran play hepatic carboxylesterase-1 (CES-1) and P-glycoprotein. To date were studied different polymorphisms that affect the pharmacokinetics of dabigatran such as rs2244613 (C > A), rs8192935 (T > C) и rs71647871 (G > A), rs1128503 (1236 C > T), rs2032582 (2677 G > T), rs1045642 (3435 C > T) и rs4148738 (G > A) and others. At the same time, there is no need of dabigatran pharmacogenetics testing in routine care. On the other side, existing literature data is often controversial, that’s why future studies are needed to answer the above-mentioned question.

Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants

“…Based on the latest data from this pharmacogenomics database, the determination of rs2244613 and rs8192935 CES1 polymorphisms, as well as rs1045642 , rs2032582 , and rs4148738 ABCB1 polymorphisms in patients taking dabigatran has a low level (3) of evidence, which prevents us from recommending the determination of these CES1 and ABCB1 genetic polymorphisms in the routine clinical practice. 28 , 60 …”